Abida, W., Aggarwal, R. R., Kouchkovsky, I. D., Lang, J. M., Cerda, J. D. L., McManus, H. D., Armstrong, A. J., Shore, N. D., Wei, A. Z., Stein, M. N., Bilusic, M., Coyne, G. H. O., Bicer, F., Mortazavi, A., Heath, E. I., Barnett, M., Flynt, J. E., Sridharan, V., Redman, J., Wise, D. R. (2026). Phase 1, dose-escalation study of KTX-2001 (an NSD2 inhibitor) alone and in combination with darolutamide for metastatic castration-resistant prostate cancer.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.7_suppl.tps276